Redesigning Healthcare Delivery: Prioritizing Patient Access and Equity

According to the World Health Expo, a conversation with Vivek Kanade, Managing Director of Siemens Healthineers for the Middle East and Africa, reframes the speed-cost-quality triangle by putting the patient at its centre. Kanade argues that healthcare innovation must be designed around access, affordability and evidence—not cutting-edge performance alone—and that value partnerships are essential if equity is to be achieved at scale. For maternal-health teams in India, the practical test is whether an innovation can fit the care pathway, remain affordable and rest on evidence relevant to the people it is meant to serve.

Start with the care pathway

As a midwife, I would read this not as a call to add more technology for its own sake, but as a reminder to examine the care pathway before an innovation is adopted. Kanade’s framing keeps three questions together: whether patients can access the service, whether it is affordable, and whether it is supported by evidence. These questions cannot be separated neatly. An intervention that looks strong in isolation may still fail to help patients if the route to care is difficult to reach or sustain.

On the ground, that means looking beyond the intervention itself and asking how it will sit within everyday clinical practice. I would begin with access, then test affordability, and only then ask what evidence exists for the intended use. This is not a claim that every service follows the same route; it is a way to prevent an appealing idea from outrunning the system and the patient it is meant to serve.

The sequence matters because the patient is not simply the final recipient of innovation. In Kanade’s formulation, the patient belongs at the centre of the design process. Access, affordability and evidence are therefore not post-launch adjustments. They are conditions to consider from the beginning, alongside the clinical need the service is supposed to address.

Equity is also an evidence question

A related report from heraldousa.com adds an important qualification. It says millions of Latinos receive diagnoses, treatments and medical recommendations based on research in which their communities have historically been underrepresented. The report argues that this gap can influence how diseases are understood, how treatments are designed and how medicine moves toward increasingly personalised models.

The article points to work published in 2026 in The Lancet Regional Health – Americas, using Mexico as an example. It says Mexico is about 20 years behind the United Kingdom and the United States in longitudinal studies, with UK Biobank and the US All of Us Research Program offered as comparisons. It also describes OriGen as an initiative seeking to expand knowledge of the Mexican population and give researchers more representative, useful information.

This is not an India-specific maternal-health result, and the supplied material does not establish what the findings mean for Indian patients. Its value for a maternal-health audience is the more fundamental question it raises: are the data behind a service representative of the people who will use it? If research does not reflect the relevant population, access to an intervention alone will not resolve the equity gap.

What practitioners should watch

The available source material does not announce a new Indian maternal-health programme, procurement decision, service cost, implementation date or measured outcome. That distinction matters. The World Health Expo discussion is a design lens, not evidence that a particular innovation has worked in India.

For teams working at district level, the sensible next step is to ask for the evidence that would support a local decision. Who was studied? How closely do those participants reflect the population served? What access and affordability constraints were considered? What value partnership would be needed to support equity at scale?

I would keep the conversation close to the care pathway and the patient experience. The central lesson from Kanade’s discussion is straightforward: innovation becomes more clinically meaningful when access, affordability and representative evidence move together.